12:00 AM
 | 
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Afinitor everolimus: Phase III started

Novartis began the double-blind, placebo-controlled, international Phase III PILLAR-2 trial to evaluate adjuvant treatment with 10 mg of oral everolimus given daily in 915 high-risk patients who achieved complete remission...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >